Keith Murphy

Dr. Keith Murphy received his training in neuroscience and behavioral genetics at the Scripps Research Institute. During his time at Scripps, he developed high-throughput tools for monitoring animal behavior during optogenetic and transgenic manipulations of discrete brain circuits. Keith then joined Stanford University as a postdoctoral fellow supported by the Ruth L. Kirschstein National Research Service Award, studying the vagus nerve and its role in sleep regulation. There, he developed the first system integrating deep-brain optical recordings of neuronal activity with ultrasound neuromodulation in freely behaving animals, enabling precise circuit control and monitoring of brain activity during natural behavior. Using this tool, he demonstrated cell type-specific effects, optimized protocols for arousal, sleep, and walking behaviors, and provided preclinical evidence of epileptiform suppression. Keith currently serves as the Co-founder and CTO of Attune Neurosciences developing next-generation lightweight wearable devices with bilateral, multi-element, electronically steered arrays. He leads the scientific investigation of neuropathic and psychiatric conditions, cognitive enhancement, and innovations enabling powerful ultrasound therapies in a wearable form factor. Attune has received support from leading investment groups, the NIH, and the US military. Keith continues to contribute to the open ultrasound neuromodulation community through his leadership in the ITRUSST practical guide, the creation of open-source software, and his collaboration with Dr. Kim Butts Pauly in developing the first open-access ultrasound neuromodulation course at Stanford University.

Attune Neurosciences
Wednesday
May 07
Converging Platforms: High-Throughput and Analytical Solutions Driving Biotech Breakthroughs
3:30 PM

-

4:15 PM

Explore how cutting-edge microelectronics, spectroscopy, advanced liquid-handling systems, and powerful bioinformatics converge to accelerate innovation across biotech, pharmaceuticals, and synthetic biology. By leveraging integrated approaches—spanning machine learning tools, next-generation lab automation, and modular high-throughput platforms—industry leaders are redefining what’s possible from early R&D to commercial-scale production. Gain insights into the core technologies and collaborative models fueling these breakthroughs, and learn how this convergence is reshaping discovery pipelines, enhancing product development, and pushing the boundaries of what we can achieve in healthcare, bioactives, and beyond.

Other Speakers

Social Media

Other

Copyright SynBioBeta 2025

Social Media

Other

Copyright SynBioBeta 2025

Social Media

Other

Copyright SynBioBeta 2025